Investing-News.Com
Information for Investors

BIOCRYST PHARM IN, (BCRX) Stock Research - Investing-News.Com
 

 Home   Market News   Analysis   Commentary   Education   Tools   Weekly Report 

Internet Search   Stock Search
   

 

BIOCRYST PHARM IN, (BCRX) Stock Research Free Stock Rating

 
Company Profile
 
BioCryst Pharmaceuticals, Inc. engages in the design, optimization, and development of small-molecule drugs that treat cancer, cardiovascular, and autoimmune diseases, as well as viral infections. The company focuses on building potent, selective inhibitors of enzymes associated with targeted diseases. BioCryst Pharmaceuticals integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to use structure-based drug design to discover and develop small molecule pharmaceuticals. Its lead product candidate, Fodosine, is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). The drug is in a Phase IIa trial for patients with T-cell leukemia and in a Phase I trial with an oral formulation in cutaneous T-cell lymphoma. The company’s pipeline products include PNP Inhibitor (BCX-4208), Hepatitis C Polymerase Inhibitors, and Tissue Factor/Factor VIIa Inhibitors. PNP Inhibitor (BCX-4208), a phase I clinical trial product, is intended for the treatment of T-cell mediated autoimmune diseases, including psoriasis. Hepatitis C Polymerase Inhibitor, a product under lead optimization stage, is intended for the treatment of viral infections. Tissue Factor/Factor VIIa, a product under lead optimization stage, is intended for the treatment of acute coronary syndromes and complications associated with cardiovascular procedures. The company has strategic agreement with Sunol Molecular Corp. to conduct research and supply of protein targets for drug design for its cardiovascular program. BioCryst Pharmaceuticals was co-founded in 1986 by Charles E. Bugg, John A. Montgomery, and William M. Spencer, III. The company is headquartered in Birmingham, Alabama.

BIOCRYST PHARM IN Related

BioCryst Pharmacueticals Develops small-molecule drugs for treatment of immunological, viral, and ... BioCryst is currently enrolling patients in clinical trials testing therapies ...
BCRX: Summary for BIOCRYST PHARM INC - Yahoo! Finance Get detailed information on BIOCRYST PHARM INC (BCRX) including quote performance, Real-Time ECN, technical chart analysis, key stats, insider transactions, and the ...
BCRX: Summary for BioCryst Pharmaceuticals, Inc. - Yahoo! Finance Get detailed information on BioCryst Pharmaceuticals, Inc. (BCRX) including quote ... New Star Analyst Rankings for BIOCRYST PHARM INC StarMine(Mon, Nov 3) ...
Sponsored Links:

Software Forces BIOCRYST PHARM IN Investors To Buy Low and Sell High The Position Cost Averaging Stock Investing Systems helps LONG-TERM investors in BIOCRYST PHARM IN buy low and sell high every time guaranteed. Click Here To Learn More

We Give Precision Entry & Exit Points on BIOCRYST PHARM IN. This software is specially designed to give precision entry and exit points on BIOCRYST PHARM IN, or any other stock you choose.
Click Here to learn how to take control of your trading.

How To Know When BIOCRYST PHARM IN Beats The Street. New Software Offers "One-Click" Stock Picks. The StockPickerRT will pick stocks for you every trading day based on earnings, volume & momentum. Maybe even BIOCRYST PHARM IN, if they make the cut.
Click Here & Learn To
Pick Winners In An Uncertain Market



Related Searches: apple computers managing underwriter  unity bank bridgewater nj  online trading systems  mx technologies fraud  matv symbols 

Research Home


Article Search


Advanced Search

StreetInsider Alerts

Latest Headlines

BioCryst named 29th fastest growing tech firm (at bizjournals.com)

Zacks #1 Rank Additions for Wednesday (Zacks.com)

Zacks #1 Rank Additions for Thursday (Zacks.com)

Zacks #1 Rank Additions for Monday (Zacks.com)

BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Financial Statements and Exhibits (EDGAR Online)

BIOCRYST PHARMACEUTICALS INC Financials (EDGAR Online Financials)

BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fin (EDGAR Online)

New Star Analyst Rankings for BIOCRYST PHARM INC (StarMine)

BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference (PR Newswire)

BioCryst trims net losses in 3Q (at bizjournals.com)

  Place Our Content On Your Site!  rss Powered By The Investing System Network
© 2006 Investing-News.Com, All Rights Reserved.